Welcome to MicroDose

	Anand V. Gumaste, Ph.D. Co-founder, President, Chief Executive Officer and Chairman of MicroDose's Board of Directors Anand V. Gumaste co-founded MicroDose in 1998 and has served as a member and Chairman of the Board of Directors since MicroDose's inception. Dr. Gumaste is a principal inventor of a majority of MicroDose's core technologies. Prior to the founding of MicroDose, Dr. Gumaste co-founded Strategic Consulting Group, located in Trenton, NJ, which focused on developing effective managed healthcare market strategies for medical device manufacturers. Prior to this, Dr. Gumaste was the director of electronics at the PA Consulting Group, Princeton, NJ, where he spent 11 years with responsibilities including developing products and technology management strategies for major corporations. Dr. Gumaste also sits on the Boards of QDose and MicroDose Defense Products, of which he is also the President. Dr. Gumaste received his Ph.D. in electronics from the University of Toronto.
	F. Scott Fleming Co-founder, Sr. Vice President, Head of Marketing Scott Fleming co-founded MicroDose in 1998 and has served as a member of the Board of Directors since MicroDose's inception. Mr. Fleming is responsible for all sales and marketing functions at MicroDose. Mr. Fleming is co-author of several patents issued to MicroDose, and has presented MicroDose at numerous conferences. Prior to the founding of MicroDose, Mr. Fleming was the National Sales Manager for Liberty Technologies, and prior to that was Business Developer for the healthcare practice of the PA Consulting Group, Princeton, NJ, specializing in drug delivery consulting. Prior to PA, Mr. Fleming spent 12 years with Schlumberger Limited, starting his career as a field engineer and rising through the sales and marketing ranks to become the North American Sales Training Manager. Mr. Fleming also sits on the Boards of QDose and MicroDose Defense Products. Mr. Fleming received his B.A. cum laude from Middlebury College in Vermont.
	Dave Byron Vice President of Research and Development Dave Byron joined MicroDose in 2002 and is responsible for all research and development activities in the company. Mr. Byron is an experienced and successful leader with over twenty-five years of performance in managing scientific, technical, and business development functions within pharmaceutical companies ranging in size from multi-national entities to start-up enterprises. Most recently, Mr. Byron was Executive Vice President of Scientific Affairs with Sheffield Pharmaceuticals. Prior to that he held high level positions with several pharmaceutical companies, including Bock Pharmacal Company, Sanofi-Winthrop Pharmaceuticals, Bristol-Myers-Squibb and Sterling Drug. Mr. Byron received a B.Sc. in Chemistry from St. John Fisher College and a Masters in Business Administration from Rensselaer Polytechnic Institute.
	Michael Martin Vice President, Licensing and Corporate Development Michael Martin, Vice President of Business Development-Mike joined MicroDose in 2006 from Odyssey Pharmaceuticals, a specialty pharmaceutical Company where he helped build the company into a $100 million branded specialty pharmaceutical company focused on respiratory and urology with 600 employees. Mr. Martin has 20 years of Business Development experience in the pharmaceutical industry covering external partnerships and acquisitions. Before Odyssey, Mike worked in the Business Development function for Roche, Sanofi-Aventis, American Cyanamid and Warner-Lambert. He has published articles in professional Journals and has an MBA in Finance from New York University and a Chartered Financial Analyst designation.
	John Krall Senior Director, Finance John Krall joined MicroDose in 2004 and is responsible for financial systems and controls. Prior to joining MicroDose, Mr. Krall was the Global Finance Manager/Controller for the PA Consulting Group, Princeton, NJ, where he spent over 14 years in two stints, starting as assistant controller. Prior to PA, Mr. Krall was North American Field Controller for Atos Origin, Murray Hill, NJ and prior to that assistant controller at Caliper Corporation of Princeton, NJ and PA Consulting. Mr. Krall received his B.Sc. in Accounting from Rider University, his Associate of Science degree in accounting from Mercer County Community College and his CPA from the State of New Jersey.
	Rajesh B. Shukla,Ph.D. Senior Director, Pharmaceutical Development Group Dr. Shukla joined MicroDose in 2007 and leads the Pharmaceutical Development Group. Dr. Shukla brings extensive experience in the pharmaceutical industry. Dr. Shukla previously managed the discovery program at Luna Innovations and identified corporate alliance partners to transition fullerene chemistry into novel chemotypes for various imaging targets. Prior to joining Luna, Dr. Shukla led efforts at Bristol-Myers Squibb for the development and launch of a Hepatitis B agent and enabled preclinical and clinical MRI biomarkers for Alzheimer’s. Dr. Shukla began his career with Bristol-Myers/Bracco Research USA, where he led the design of MRI contrast agents. He earned a B.Sc. in biochemistry from Lehigh University, a doctorate in Chemistry/Biophysics from Carnegie-Mellon University and was a Postdoctoral Fellow in the Department of Chemistry at Yale University.
	Ron Britt, Ph.D. Director of Quality Assurance Ron Britt joined MicroDose in 2004, and is responsible for quality assurance, quality systems and controls. Dr. Britt has almost 30 years experience in the pharmaceutical industry in the disciplines of chemistry, research and quality systems. Prior to joining MicroDose, Dr. Britt was Sr. Compliance Specialist/Technical Investigator, Quality Assurance, at Novartis Pharmaceuticals, and prior to that over 20 years in a variety of positions at Ciba Pharmaceuticals and Ciba-Geigy Corporation. Dr. Britt received his B.S. in Chemistry from Fairleigh Dickinson University, NJ, and his Ph.D. in Organic Chemistry from Fordham University in NYC.

Please visit our User Agreement. Your continued use of this site will automatically constitute your agreement to be bound by all the terms and conditions of the User Agreement.